Oral Drug Delivery Videos
-
Developing And Manufacturing Minitablets To Extend Drug Lifecycle
1/27/2025
Pharmaceutical companies should leverage oral minitablets to extend drug lifecycles, optimize dosing, and improve patient-centric solutions while overcoming manufacturing challenges.
-
Technology To Overcome Absorption Hurdles And Solubility Limitations
3/6/2024
For poorly soluble drugs, overcoming absorption hurdles can hinder development. Explore a solution that empowers researchers to overcome solubility limitations and accelerate drug development.
-
The Future Of Oral Solid Dose Development And Innovation
2/27/2025
Tom Sellig, CEO of Adare, discusses the ongoing relevance of small molecules, oral solid dose development, trends like GLP-1, and innovations like 3D printing in pharmaceuticals.
-
Miami Clinical Pharmacology Facility Tour
3/7/2022
Our new, state-of-the-art compounding pharmacy supports the rapid and cost-effective preparation of dosage forms including oral solutions, suspensions, drug or powder in capsule or bottle, and sterile preparations.
-
What Is the Impact of the New QMSR on 21 CFR Part 4?
7/11/2024
In this segment of the Drug Delivery Leader Live event New FDA QMSR: Its Role in Part 4 Compliance for Combination Products, DDL Executive Editor Fran DeGrazio enlists consultants Laurie Auerbach of Compliance Prodigies and Ed Bills of Edwin Bills Consultant to summarize where Part 4 is documented in the new guidance.
-
PBPK Modeling: Mitigating Absorption Risks In Early Drug Development
Discover how PBPK models combined with in vitro tools and solubility enhancement expertise can be used to identify and mitigate absorption risks in early drug development.
-
A Roadmap For Early Development To Commercial Manufacturing
Learn how to avoid common pitfalls in the transfer and scale-up process using an integrated approach, with industry experts sharing key considerations when planning for scale-up of a development program.
-
The Role of ISO 13485 in the New QMSR
7/11/2024
What does the addition of ISO 13485 as reference in the new QMSR mean for those working to comply with 21 CFR 820? In this segment of the Drug Delivery Leader Live event New FDA QMSR: Its Role in Part 4 Compliance for Combination Products, consultant Laurie Auerbach of Compliance Prodigies explains the relationship between the two guidance documents.
-
Who Is Responsible For Design Controls?
7/11/2024
In this segment of the Drug Delivery Leader Live event New FDA QMSR: Its Role in Part 4 Compliance for Combination Products, DDL Executive Editor Fran DeGrazio asks consultants Laurie Auerbach of Compliance Prodigies and Ed Bills of Edwin Bills Consultant to identify which organization in a combination product manufacturing process are responsible for design controls – the sponsor company, the contracted component provider, or both.
-
Transforming Drug Delivery. Transforming Lives.
8/29/2024
Watch this introduction to Adare Pharma Solutions, a global technology driven CDMO providing product development through commercial manufacturing expertise focused on oral dosage forms for the Pharmaceutical industry.